证券代码：000766 证券简称：通化金马 公告编号：2020-57 通化金马药业集团股份有限公司 关于参加 2020 年吉林辖区上市公司投资者网上集体接待日活动的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，通化金马药业集团股份有限公司（以下简 称"公司"）将参加由吉林证监局、吉林省证券业协会、深圳市全景网络有限公司共 同举办的"提高公司质量 做受尊敬的上市公司--2020 年吉林辖区上市公司投资者网 上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举行， 投资者可以登陆"全景·路演天下"网站（http://rs.p5w.net）参与公司本次投资 者集体接待日活动,时间为 2020 年 8 月 21 日（周五）15:30 至 17:00。 届时公司总经理、董事会秘书、财务总监等将通过网络在线问答互动的形式， 与投资者就公司治理、发展经营情况、融资情况和可持续发展等投资者关注的问题 进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 欢迎广大投资者积极参 ...

Financial Performance - The company's operating revenue for 2019 was CNY 1,977,206,434.29, a decrease of 5.60% compared to CNY 2,094,549,374.90 in 2018[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 2,041,890,393.46, representing a decline of 717.15% from a profit of CNY 330,858,116.24 in 2018[23] - The net cash flow from operating activities was CNY 74,861,078.98, down 56.15% from CNY 170,722,975.82 in the previous year[23] - The total assets at the end of 2019 were CNY 4,698,048,449.36, a decrease of 21.66% from CNY 5,997,069,913.93 at the end of 2018[23] - The net assets attributable to shareholders of the listed company decreased by 44.16% to CNY 2,630,930,917.49 from CNY 4,711,657,322.38 in 2018[23] - The basic earnings per share for 2019 was -CNY 2.11, a decline of 720.59% compared to CNY 0.34 in 2018[23] - The weighted average return on net assets was -57.92%, down 65.20% from 7.28% in the previous year[23] - The company reported a significant increase in losses due to various operational challenges and market conditions[23] Revenue Breakdown - The revenue from traditional Chinese medicine increased by 7.06% to CNY 762,453,572.11, accounting for 38.56% of total revenue[49] - The revenue from chemical drugs decreased by 11.26% to CNY 1,205,353,998.12, representing 60.96% of total revenue[49] - The Northeast region saw a significant revenue decline of 41.95%, with revenue dropping to CNY 197,481,411.07[49] - The company reported a total sales volume of 59,692,828 boxes in the pharmaceutical sector, an increase of 3.18% from the previous year[53] Operational Strategies - Future outlook includes a focus on new product development and market expansion strategies[6] - The company plans to enhance its internal management and control systems to improve operational efficiency and risk management[36] - The company is focusing on expanding its market presence through various sales channels, including direct sales to hospitals and e-commerce platforms[36] - The company has adjusted its marketing strategy to mitigate the impact of policy changes, enhancing internal management and optimizing its sales team[44] - The company will enhance internal management and information sharing to improve operational efficiency and reduce management costs[115] Research and Development - Research and development (R&D) investment reached ¥87,805,670.72 in 2019, an increase of 18.15% compared to 2018[69] - The company reported a significant increase in capitalized R&D expenses by 197.84%, attributed to the increased enrollment in the clinical trial for a new drug[69] - The number of R&D personnel increased by 6.15% to 328, representing 15.50% of the total workforce[69] - The company is conducting a Phase III clinical trial for its new drug, with nearly 400 cases enrolled[44] - The company plans to accelerate the Phase III clinical trial of its new drug for Alzheimer's disease, aiming to complete all case enrollments by the end of 2020[115] Acquisitions and Investments - The company plans to acquire 85% stakes in Jixi Jikuang Hospital and Shuangyashan Shuangkuang Hospital for a total preliminary consideration of ¥1,530,000,000, aiming to expand its presence in the healthcare industry[44] - The company has invested a total of RMB 128 million in the payment transaction price, achieving a 100% investment progress[99] - The company has invested RMB 20 million in the Saintai Biological Phase III construction project, with a progress rate of 96.21%[99] - The company has established partnerships for industrial hemp projects, focusing on breeding, planting, extraction, and deep processing, to enhance its product offerings and market position[44] Financial Management - The total liabilities increased significantly, with long-term borrowings rising to ¥983,211,736.24, a change of 18.07% from the previous year[78] - The net cash flow from financing activities increased by 527.55% to ¥703,289,724.02, driven by higher loan amounts compared to the previous year[73] - The company has a total of ¥6,708.28 million in unused fundraising, with part of the idle funds temporarily used to supplement working capital[91] - The company has not engaged in any securities or derivative investments during the reporting period[86][87] Shareholder Commitments - The company has received commitments from its major shareholders to avoid any business that competes directly or indirectly with its operations[135] - The company has confirmed that there is no existing competition between its operations and those of its major shareholders' other businesses[135] - The company will ensure that any related party transactions do not harm the legal rights of other shareholders[132] - The company confirmed its commitment to protect the rights of all shareholders, especially minority shareholders, during the equity transfer process[138] Compliance and Governance - The company has maintained a good integrity status, with no significant debts or court judgments unfulfilled during the reporting period[171] - The company has not faced any situations that could lead to suspension or termination of listing after the annual report disclosure[168] - The company has not experienced any major accounting errors requiring retrospective restatement during the reporting period[162] - The company appointed Zhongzhun Accounting Firm as its internal control audit institution for the year, with an audit fee of 650,000 CNY[167]

通化金马药业集团股份有限公司 2019 年年度报告全文 通化金马药业集团股份有限公司 2019 年年度报告 2020 年 04 月 1 通化金马药业集团股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2019 年年度报告全文 目录 | --- | --- | |-------------------------------------------------------------------------------------|-------| | | | | 第一节 ...

Financial Performance - The company's operating revenue for Q1 2020 was ¥151,452,899.87, a decrease of 63.01% compared to ¥409,397,546.32 in the same period last year[3] - The net profit attributable to shareholders was -¥44,419,586.26, representing a decline of 187.21% from ¥50,931,985.61 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥56,565,311.12, a decrease of 239.04% compared to ¥40,683,222.82 last year[3] - Operating revenue decreased by 63.01% due to the impact of the pandemic on sales[9] - The net profit for Q1 2020 was a loss of ¥44,659,282.41, compared to a profit of ¥50,644,468.36 in Q1 2019, indicating a shift in financial performance[26] - The net profit for the first quarter of 2020 was CNY 14,241,505.68, a significant decrease compared to CNY 87,921,660.43 in the same period last year[30] - Basic and diluted earnings per share for Q1 2020 were both -¥0.0460, compared to ¥0.0527 in the previous year[28] - The total comprehensive income for the first quarter was CNY 14,241,505.68, compared to CNY 87,921,660.43 in the previous year[31] Cash Flow - The net cash flow from operating activities improved to ¥26,046,278.34, a 140.84% increase from -¥63,776,462.86 in the same period last year[3] - Net cash flow from operating activities increased by 140.84% due to a reduction in payments for goods and prepayments compared to the same period last year[9] - The net cash flow from investing activities decreased by 841.59% due to the acquisition of a 15% stake in Longmei Hospital[9] - The net cash flow from financing activities increased by 245,547.21% due to an increase in loans compared to the same period last year[9] - The cash outflow from investing activities was CNY 494,586,818.61, compared to CNY 337,440,947.98 in the same period last year[33] - The net cash flow from investing activities was -489,480,070.21 CNY, indicating significant cash outflows related to investments[36] - The net cash flow from financing activities was 182,702,800.25 CNY, primarily driven by cash received from borrowings of 198,750,000.00 CNY[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,658,224,363.33, an increase of 20.44% from ¥4,698,048,449.36 at the end of the previous year[3] - The total liabilities reached CNY 3,036,899,387.00, up from CNY 2,032,064,190.62, which is an increase of approximately 49.4%[20] - The company's equity attributable to shareholders decreased to CNY 2,586,511,331.23 from CNY 2,630,930,917.49, a decline of about 1.7%[21] - The total liabilities as of the end of Q1 2020 were ¥2,138,654,372.63, compared to ¥1,153,714,757.53 at the end of the previous year, indicating increased leverage[24] - The total current liabilities amounted to CNY 911,454,123.66, slightly up from CNY 905,034,652.99, indicating a marginal increase of about 0.5%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,599[5] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 24.98% of the shares[5] - The company did not engage in any repurchase transactions during the reporting period[6] Investments and Acquisitions - The company plans to acquire 85% stakes in Jixi Jikuang Hospital and Shuangyashan Shuangkuang Hospital for an initial consideration of 153 million yuan[10] - Prepayments surged by 1489.89% due to the acquisition of a 15% stake in Longmei Hospital and prepayments for the acquisition of funds from Heilongjiang Property Exchange[9] - Goodwill increased by 92.23% as a result of the acquisition of Harbin Shengtai Pharmaceutical's stake in Harbin Cezhan Pharmaceutical[9] Research and Development - Research and development expenses rose by 128.63% due to increased investment in R&D projects[9] - Research and development expenses increased to ¥8,425,926.98 in Q1 2020, up from ¥3,685,405.11 in the same period last year, highlighting a focus on innovation[25] Government Support - The company received government subsidies amounting to ¥14,840,456.33 during the reporting period[4] Financial Structure - The company's cash and cash equivalents increased to CNY 638,244,758.35 from CNY 150,219,230.03, reflecting a growth of approximately 325.5%[22] - The company incurred a credit impairment loss of CNY -6,168,475.17 during the quarter[30] - The company has a long-term debt of 983,211,736.24 CNY, indicating a significant leverage position[40]

通化金马药业集团股份有限公司 2019 年第三季度报告全文 通化金马药业集团股份有限公司 2019 年第三季度报告 2019 年 10 月 1 通化金马药业集团股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------|-------------------------|---------- ...

通化金马药业集团股份有限公司 2019 年半年度报告全文 通化金马药业集团股份有限公司 2019 年半年度报告 2019 年 08 月 1 通化金马药业集团股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人战红君、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中涉及未来计划、发展战略等前瞻性陈述，不构成公司对投 资者的实质承诺，敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2019 年半年度报告全文 目录 | --- | --- | |-------------------------------------------------------------------------------------|-------| | | | ...

Financial Performance - The company's operating revenue for 2018 was CNY 2,094,549,374.90, representing a 37.67% increase compared to CNY 1,521,410,294.36 in 2017[10]. - The net profit attributable to shareholders for 2018 was CNY 330,858,116.24, up 28.30% from CNY 257,879,255.54 in 2017[10]. - The net cash flow from operating activities increased significantly by 545.84% to CNY 170,722,975.82 from CNY 26,434,194.72 in 2017[10]. - The basic earnings per share for 2018 was CNY 0.34, a 25.93% increase from CNY 0.27 in 2017[10]. - Total assets at the end of 2018 reached CNY 5,997,069,913.93, a 4.72% increase from CNY 5,726,837,493.11 at the end of 2017[10]. - The net assets attributable to shareholders increased by 7.55% to CNY 4,711,657,322.38 from CNY 4,380,799,206.14 in 2017[11]. - The company reported a decrease of 16.63% in net profit after deducting non-recurring gains and losses, totaling CNY 204,684,082.46 in 2018[10]. - The weighted average return on equity for 2018 was 7.28%, up from 6.07% in 2017[10]. - The company achieved a revenue of ¥2,094,549,374.90 in 2018, representing a 37.67% increase year-over-year[22]. - The net profit attributable to shareholders was ¥330,858,116.24, marking a 28.30% increase compared to the previous year[22]. Operational Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on research, production, and sales of various medical products, including oncology and gastrointestinal medications[18]. - The company has adopted a "production based on sales" model, aligning production plans with sales forecasts and inventory levels[18]. - The marketing strategy has shifted towards precision marketing and academic promotion, enhancing the sales network and capabilities[18]. - The company has implemented a dual-driven strategy focusing on mergers and acquisitions while enhancing internal management and market coverage[22]. - The company has strengthened its marketing strategy by transitioning from traditional marketing to academic and precision marketing approaches[22]. Research and Development - The company has a total of 41 invention patents and 25 utility model patents, with 3 invention patents and 3 utility model patents currently under review[21]. - The company is advancing the clinical trial of its new drug, Succinylated Tetrahydroaminoacridine, with over 150 cases enrolled in the study[22]. - R&D expenses rose by 23.06% to ¥74,317,857.37, with R&D personnel increasing by 9.19% to 309[37]. - The company aims to enhance its R&D and innovation capabilities, focusing on a dual strategy of "internal growth + external expansion" to drive development[58]. Market and Industry Trends - The pharmaceutical industry is expected to maintain robust growth due to economic development, improved healthcare systems, and increasing health awareness among the population[19]. - The company faces industry policy risks due to reforms and price reductions in the pharmaceutical sector, which may impact sales revenue and expenses[62]. - The company is addressing the risk of declining drug prices due to external market conditions and rising production costs[63]. - The pharmaceutical industry in China is undergoing significant changes due to policy reforms, which present both opportunities and challenges for the company[58]. Financial Management and Investments - The company has made investments in equity stakes in Beijing Minkan Baicao Pharmaceutical Technology Co., Ltd. and Shanghai Shijian Biotechnology Co., Ltd. during the reporting period[20]. - The total investment amount for the reporting period was ¥218,469,710.03, representing a 111.29% increase compared to ¥103,395,590.70 in the same period last year[44]. - The company completed a significant equity investment in Jiangxi Fengma Pharmaceutical Co., Ltd. for ¥1,900,000, acquiring 100% ownership[44]. - The company raised a total of ¥1,688,000,000.00 through a private placement, with a net amount of ¥1,664,306,994.14 after deducting issuance costs[49]. Corporate Governance and Compliance - The company has committed to avoiding competition with its subsidiaries and has established measures to reduce and regulate related party transactions[72]. - The company has made commitments to comply with relevant regulations and ensure fair pricing in related party transactions[72]. - The company’s independent directors have fulfilled their responsibilities and ensured the protection of minority shareholders' rights[68]. - The company has established a governance structure that allows for independent exercise of authority by its internal management[74]. Environmental and Social Responsibility - The company actively fulfilled its social responsibilities, focusing on environmental protection and employee rights[117]. - The company received the "Outstanding Helping Enterprise" title from the local poverty alleviation office for its efforts in poverty alleviation[120]. - The company processed a total of 89,129 tons of wastewater in 2018, achieving a 100% compliance rate for water quality standards[126]. - The company invested 8.2 million RMB to build a new wastewater treatment plant with a capacity of 1,000 tons per year, which has been operating stably since August 2018[125]. Shareholder Information - The company did not distribute any cash dividends in 2018, maintaining a cash dividend policy of 0.00% of net profit for the past three years[69]. - The company has a long-term commitment to fulfill its promises regarding related party transactions and competition avoidance[72]. - The total number of shares held by the top ten unrestricted shareholders is 220,000,000, indicating concentrated ownership[137]. - The company plans to release 63,291,139 shares from lock-up on June 13, 2018, and an additional 121,765,601 shares on January 19, 2019[133].

Financial Performance - The company's operating revenue for Q1 2019 was ¥409,397,546.32, representing a 13.65% increase compared to ¥360,211,471.99 in the same period last year[3] - The net profit attributable to shareholders was ¥50,931,985.61, a decrease of 12.88% from ¥58,463,126.37 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥40,683,222.82, down 27.41% from ¥56,041,854.52 in the previous year[3] - Basic earnings per share decreased to ¥0.0527, down 12.89% from ¥0.0605 year-on-year[3] - Total operating revenue for the current period reached ¥409,397,546.32, an increase of 13.6% compared to ¥360,211,471.99 in the previous period[24] - Net profit for the current period was ¥50,644,468.36, a decrease of 13.5% from ¥58,210,800.73 in the previous period[25] - Operating profit for the current period was ¥61,418,909.01, down 8.7% from ¥67,347,487.96 in the previous period[25] - The company reported a total comprehensive income of ¥87,921,660.43 for the current period, compared to ¥57,891,059.46 in the previous period, indicating a significant increase[29] - The total profit for the current period was ¥87,708,437.06, compared to ¥57,171,332.40 in the previous period, showing an increase of 53.3%[28] Cash Flow - The net cash flow from operating activities was negative at ¥63,776,462.86, a decline of 229.58% compared to ¥49,217,259.41 in the same period last year[3] - Cash inflow from operating activities was CNY 504,928,999.19, an increase from CNY 425,445,949.41 in the previous period, representing a growth of approximately 18.6%[31] - The net cash flow from operating activities was -CNY 63,776,462.86, compared to a positive cash flow of CNY 49,217,259.41 in the previous period[31] - Cash outflows for operating activities totaled CNY 568,705,462.05, up from CNY 376,228,690.00, indicating a significant increase of about 51%[31] - The cash inflow from investment activities was CNY 285,581,457.88, down from CNY 326,334,103.86, reflecting a decrease of approximately 12.5%[32] - The net cash flow from investment activities was -CNY 51,859,490.10, compared to -CNY 188,650,757.48 in the previous period, showing an improvement[32] - Cash inflow from financing activities was CNY 30,000,000.00, a decrease from CNY 86,665,377.01 in the previous period[32] - The net cash flow from financing activities was CNY 402,932.99, down from CNY 6,843,124.89, indicating a decline[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,915,441,089.40, a decrease of 1.36% from ¥5,997,069,913.93 at the end of the previous year[3] - The total liabilities decreased from CNY 1,249,313,522.82 to CNY 1,117,040,229.93, a reduction of approximately 10.55%[17] - The total owner's equity increased from CNY 4,747,756,391.11 to CNY 4,798,400,859.47, reflecting a growth of about 1.06%[18] - The company's current assets rose from CNY 891,819,841.71 to CNY 967,850,617.45, an increase of approximately 8.54%[20] - The non-current assets increased from CNY 3,766,797,515.22 to CNY 3,784,199,813.89, showing a growth of about 0.46%[20] - The total cash and cash equivalents at the end of the period were CNY 199,399,014.66, down from CNY 229,673,430.51[32] - The total liabilities to equity ratio improved from 1.63 to 1.47, indicating a stronger equity position[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,349[5] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 45.97% of the shares, totaling 444,293,544 shares[5] - The net assets attributable to shareholders increased by 1.07% to ¥4,798,400,859.47 from ¥4,747,756,391.11 at the end of the previous year[3] Government Subsidies and Other Income - The company received government subsidies amounting to ¥12,318,144.41 during the reporting period[4] - Other income increased by 187.63% due to higher government subsidies received compared to the previous year[9] Research and Development - Research and development expenses increased to ¥3,685,405.11, compared to ¥3,206,428.27 in the previous period, reflecting a growth of 14.9%[24] Investment and Equity - Investment income decreased by 149.00% due to adjustments related to the equity method for newly acquired R&D institutions[9] - Long-term equity investments increased by 30.44% due to the acquisition of equity in Beida Shijia[9] - The company achieved an investment income of ¥97,770,934.63, up from ¥49,739,720.21 in the previous period, representing a growth of 96.5%[28] Operational Insights - The company is actively promoting a major asset restructuring to enhance profitability and improve shareholder returns[10] - The first quarter report of Tonghua Golden Horse Pharmaceutical Group Co., Ltd. is unaudited[42] - The report was released on April 26, 2019[42] - No specific financial performance metrics or user data were provided in the document[42] - Future outlook and performance guidance were not discussed in the report[42] - There were no mentions of new products or technology development in the document[42] - Market expansion and mergers or acquisitions were not addressed in the report[42] - Other new strategies were not outlined in the document[42] - The report does not include any financial figures or percentages[42] - The company did not provide any insights into operational performance or market trends[42] - The document lacks detailed analysis or commentary on the company's financial health[42]

Financial Performance - The company's operating revenue for 2018 was CNY 2,094,549,374.90, representing a 37.67% increase compared to CNY 1,521,410,294.36 in 2017[10] - The net profit attributable to shareholders for 2018 was CNY 330,858,116.24, up 28.30% from CNY 257,879,255.54 in 2017[10] - The net cash flow from operating activities increased significantly by 545.84% to CNY 170,722,975.82 from CNY 26,434,194.72 in 2017[10] - The basic earnings per share for 2018 was CNY 0.34, a 25.93% increase from CNY 0.27 in 2017[10] - Total assets at the end of 2018 were CNY 5,997,069,913.93, reflecting a 4.72% increase from CNY 5,726,837,493.11 at the end of 2017[10] - The net assets attributable to shareholders increased by 7.55% to CNY 4,711,657,322.38 from CNY 4,380,799,206.14 in 2017[11] - The company reported a decrease of 16.63% in net profit after deducting non-recurring gains and losses, totaling CNY 204,684,082.46 in 2018 compared to CNY 245,507,558.17 in 2017[10] - The weighted average return on net assets for 2018 was 7.28%, an increase from 6.07% in 2017[10] Revenue and Sales - The quarterly operating revenue for Q4 2018 was CNY 721,553,815.66, contributing significantly to the annual total[13] - Non-operating income for 2018 amounted to ¥126,174,033.78, a significant increase from ¥12,371,697.37 in 2017[15] - The company reported a non-operating loss from the disposal of non-current assets of ¥130,865,120.06 in 2018, compared to a gain of ¥2,751,825.20 in 2017[14] - The revenue from the pharmaceutical industry accounted for 100% of total operating revenue, with a gross profit margin of 83.70%[27] - The sales volume of traditional Chinese medicine reached 57,855,669 boxes, an increase of 7.61% from 2017[28] - The company reported a significant increase in revenue from the North China region, which grew by 67.02% to ¥366,829,884.56[26] - The gross profit margin for chemical drugs was 92.08%, with revenue of ¥1,413,371,404.27, reflecting a year-on-year increase of 45.77%[27] Investments and Acquisitions - The company has made investments in equity stakes in Beijing Minkan Baicao Pharmaceutical Technology Co., Ltd. and Shanghai Shijian Biotechnology Co., Ltd.[20] - The company acquired 100% equity of Yuanshou Bio, which specializes in probiotic products, enhancing its market share in the domestic probiotic market[22] - The company is in the process of acquiring the controlling stake in five comprehensive hospitals to expand into the healthcare industry, although the acquisition is pending regulatory approval[22] - The company has completed a 100% acquisition of Jiangxi Fengma Pharmaceutical Co., Ltd. for ¥1,900,000.00, with an investment gain of ¥5,944,297.03 reported[45] - The company plans to acquire 84.14% stakes in multiple hospitals for a total transaction amount of CNY 2,190,516,460, and aims to raise up to CNY 690,495,000 through a private placement[103] Research and Development - The company’s R&D investment has increased to strengthen its core competitiveness and improve product quality[18] - The number of R&D personnel increased by 9.19% to 309, representing 14.51% of the total workforce[38] - Research and development expenses increased by 23.06% to ¥74,317,857.37, representing 3.55% of total revenue, down from 3.97% the previous year[38] - The company intends to enhance its R&D capabilities, with plans to initiate clinical trials for a key product in 30 hospitals by the end of 2019[62] Marketing and Strategy - The company’s marketing strategy has shifted towards professional academic marketing and precision marketing, enhancing its sales capabilities[18] - The company has strengthened its marketing strategy by transitioning from traditional marketing to specialized academic marketing and precision marketing[22] - The marketing strategy will be strengthened to increase sales scale and market share, with a focus on developing a diversified sales network across the country[61] Corporate Governance and Shareholder Relations - The company has established mechanisms to protect the rights of minority shareholders during decision-making processes[69] - The company has committed to minimizing related party transactions and ensuring fair pricing in unavoidable cases[73] - The company has a long-term commitment to comply with relevant regulations and protect the interests of all shareholders[73] - The company has not engaged in any new product or technology development announcements during the reporting period[69] Environmental and Social Responsibility - The company has maintained a strong commitment to environmental protection, with no major safety incidents or environmental issues reported during the reporting period[118] - The company processed a total of 89,129 tons of wastewater in 2018, achieving a 100% compliance rate for water quality standards[127] - The company invested 8.2 million yuan to build a new wastewater treatment plant with a capacity of 1,000 tons per year, which has been operating stably since August 2018[126] - The company actively fulfilled its social responsibilities, ensuring compliance with laws and regulations while enhancing corporate governance[118] - The company received the "Outstanding Helping Enterprise" title from the local poverty alleviation office for its efforts in employment and economic development in impoverished areas[121] Financial Management and Audit - The audit report issued by Zhongzhun Accounting Firm confirmed that the financial statements fairly reflect the company's financial position and operating results[181] - The management is responsible for ensuring the financial statements are prepared in accordance with accounting standards and for maintaining effective internal controls[187] - The audit identified revenue recognition as a key audit matter due to the inherent risk of management manipulating revenue to meet targets[183] - The company evaluated the effectiveness of internal controls related to revenue recognition and assessed the timing of revenue recognition against accounting standards[183] Risks and Challenges - The company faces risks from industry policy changes, including drug price reductions and stricter regulations, which may impact sales revenue and expenses[63] - Continuous pressure on profit margins is expected due to declining drug prices and rising production costs[64] - There is a risk of goodwill impairment due to past acquisitions if the acquired companies do not achieve stable growth[65] - The company is focused on reducing risks in drug development through careful project evaluation and increased collaboration[65]

通化金马药业集团股份有限公司 2018 年年度报告全文 通化金马药业集团股份有限公司 2018 年年度报告 2019 年 04 月 1 通化金马药业集团股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2018 年年度报告全文 目录 | --- | --- | |--------------------------------------------------------------------------------------------------------- ...